A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients With 1-4 Brain Metastases.
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Brain metastases
- Focus Adverse reactions; Biomarker
- 14 Jul 2017 Status changed from active, no longer recruiting to completed.
- 18 Aug 2016 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
- 18 Aug 2016 Status changed from recruiting to active, no longer recruiting.